 <h1>Didronel Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>etidronate</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about etidronate. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Didronel.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to etidronate: oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, etidronate (the active ingredient contained in Didronel) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking etidronate:</p><p>
<i>More common</i>
</p><ul>
<li>Bone pain or tenderness (increased, continuing, or returningâ€”in patients with Paget's disease)</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Bone fractures, especially of the thigh bone</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Abdominal or stomach pain or burning</li>
<li>bloody, black, or tarry stools</li>
<li>chest pain</li>
<li>chills</li>
<li>cough or hoarseness</li>
<li>fever</li>
<li>general feeling of tiredness or weakness</li>
<li>hives</li>
<li>lower back or side pain</li>
<li>noisy breathing</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>skin rash or itching</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots on the lips or inside the mouth</li>
<li>swelling of the arms, legs, face, lips, tongue, or throat</li>
<li>swollen glands</li>
<li>tightness in the chest</li>
<li>unusual bleeding or bruising</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Blistering, peeling, loosening of the skin</li>
<li>bone, joint, or muscle pain that is severe and occasionally disabling</li>
<li>burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings</li>
<li>difficulty in moving</li>
<li>difficulty in swallowing</li>
<li>discouragement</li>
<li>feeling sad or empty</li>
<li>heartburn</li>
<li>heavy jaw feeling</li>
<li>irritability</li>
<li>lack of appetite</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>loosening of a tooth</li>
<li>loss of interest or pleasure</li>
<li>loss of memory</li>
<li>pain or burning in the throat</li>
<li>pain, swelling, or numbness in the mouth or jaw</li>
<li>problems with memory</li>
<li>rash with flat lesions or small raised lesions on the skin</li>
<li>red irritated eyes</li>
<li>red skin lesions, often with a purple center</li>
<li>redness or discoloration of the skin</li>
<li>seeing, hearing, or feeling things that are not there</li>
<li>trouble concentrating</li>
<li>trouble sleeping</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
</ul><p>
<i>Get emergency help immediately if any of the following symptoms of overdose occur while taking etidronate:</i>
</p><p>
<i>Symptoms of overdose</i>
</p><ul>
<li>Abdominal or stomach cramps</li>
<li>confusion</li>
<li>convulsions</li>
<li>difficulty in breathing</li>
<li>irregular heartbeats</li>
<li>mood or mental changes</li>
<li>muscle cramps in the hands, arms, feet, legs, or face</li>
<li>numbness and tingling around the mouth, fingertips, or feet</li>
<li>shortness of breath</li>
<li>tremor</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of etidronate may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Diarrhea</li>
<li>nausea</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Burning feeling in the chest or stomach</li>
<li>hair loss, thinning of hair</li>
<li>headache</li>
<li>indigestion</li>
<li>leg cramps</li>
<li>stomach upset</li>
<li>tenderness in the stomach area</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to etidronate: intravenous solution, oral tablet</i></p><h3>Gastrointestinal</h3><p>Gastrointestinal side effects are more common with higher doses (10 to 20 mg/kg) and may be alleviated by dividing the daily dose.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Diarrhea, nausea </p>
<p><b>Rare</b> (less than 0.1%): Burning of the tongue</p>
<p><b>Frequency not reported</b>: Exacerbation of peptic ulcer disease including perforation in a few patients, gastritis</p>
<p><b>Postmarketing reports</b>: Esophagitis; glossitis, duodenal ulcer<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Rare</b> (less than 0.1%): Erythema multiforme, alopecia</p>
<p><b>Frequency not reported</b>: Angioedema, follicular eruption, macular rash, maculopapular rash, pruritus, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Rare</b> (less than 0.1%): Hypersensitivity reactions, including angioedema, urticaria, rash, pruritus<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Uncommon</b> (0.1% to 1%): Arthropathies (arthralgia and arthritis)</p>
<p><b>Rare</b> (less than 0.1%): Atypical subtrochanteric and diaphyseal femoral fractures</p>
<p><b>Frequency not reported</b>: Osteonecrosis of the jaw (ONJ), leg cramps, increased or recurrent bone pain at pagetic sites and onset of pain at previously asymptomatic sites</p>
<p><b>Postmarketing reports</b>: Bone fracture, osteomalacia<sup>[Ref]</sup></p><p>At higher doses the incidence of increased or recurrent bone pain at pagetic sites and/or onset of pain at previously asymptomatic sites rise.  When therapy continues, pain resolves in some patients but persists in others.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Rare</b> (less than 0.1%): Confusion</p>
<p><b>Postmarketing reports</b>: Depression, hallucination<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Rare</b> (less than 0.1%): Paresthesia, peripheral neuropathy</p>
<p><b>Frequency not reported</b>: Headache</p>
<p><b>Postmarketing reports</b>: Neuropsychiatric events including amnesia<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Rare</b> (less than 0.1%): Exacerbation of asthma<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Rare</b> (less than 0.1%): Leukopenia, agranulocytosis pancytopenia<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Saunders RL, Jr "Appearance of a gastric ulcer during diphosphonate therapy in a woman with CRST syndrome." South Med J 70 (1977): 1327-9</p><p id="ref_2">2. Beauchesne MF, Miller PF "Etidronate and alendronate in the treatment of postmenopausal osteoporosis." Ann Pharmacother 33 (1999): 587-99</p><p id="ref_3">3. Jaworski RC, Gibson M "Mitral and aortic valve abnormalities in a patient with fibrodysplasia ossificans progressiva." Pathology 15 (1983): 325-8</p><p id="ref_4">4. vanStaa TP, Leufkens H, Abenhaim L, Cooper C "Postmarketing surveillance of the safety of cyclic etidronate." Pharmacotherapy 18 (1998): 1121-8</p><p id="ref_5">5. "Product Information. Didronel Tablets (etidronate)." Procter and Gamble Pharmaceuticals, Cincinnati, OH. </p><p id="ref_6">6. Jones PB, McCloskey EV, Kanis JA "Transient taste-loss during treatment with etidronate ." Lancet 2 (1987): 637</p><p id="ref_7">7. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_8">8. "Product Information. Didronel I.V. Infusion (etidronate)." MGI Pharma Inc, Minnetonka, MN. </p><p id="ref_9">9. Lourwood DL "The pharmacology and therapeutic utility of bisphosphonates." Pharmacotherapy 18 (1998): 779-89</p><p id="ref_10">10. Evans RA, MacDonald D "Diphosphonates and painful feet." Aust N Z J Med 13 (1983): 175-6</p><p id="ref_11">11. Evans RA, Dunstan CR, Hills E, Wong SY "Pathologic fracture due to severe osteomalacia following low-dose diphosphonate treatment of Paget's disease of bone." Aust N Z J Med 13 (1983): 277-9</p><p id="ref_12">12. Gallacher SJ, Boyle IT, Capell HA "Pseudogout associated with the use of cyclical etidronate therapy." Scott Med J 36 (1991): 49</p><p id="ref_13">13. Mautalen C, Gonzalez D, Blumenfeld EL, Santini Araujo E, Schajowicz F "Spontaneous fractures of uninvolved bones in patients with Paget's disease during unduly prolonged treatment with disodium etidronate (EHDP)." Clin Orthop Jun (1986): 150-5</p><p id="ref_14">14. Boyce BF, Smith L, Fogelman I, Johnston E, Ralston S, Boyle IT "Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease." Lancet 1 (1984): 821-4</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Didronel (etidronate)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Drug class: bisphosphonates</li>
<li>FDA Alerts (3)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Didronel &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Heterotopic Ossification, Spinal Cord Injury</li>
<li>Heterotopic Ossification, Total Hip Arthroplasty</li>
<li>Hypercalcemia of Malignancy</li>
<li>Osteoporosis</li>
<li>Paget's Disease</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to etidronate: intravenous solution, oral tablet</i></p><h3>Gastrointestinal</h3><p>Gastrointestinal side effects are more common with higher doses (10 to 20 mg/kg) and may be alleviated by dividing the daily dose.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Diarrhea, nausea </p><p><b>Rare</b> (less than 0.1%): Burning of the tongue</p><p><b>Frequency not reported</b>: Exacerbation of peptic ulcer disease including perforation in a few patients, gastritis</p><p><b>Postmarketing reports</b>: Esophagitis; glossitis, duodenal ulcer<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Rare</b> (less than 0.1%): Erythema multiforme, alopecia</p><p><b>Frequency not reported</b>: Angioedema, follicular eruption, macular rash, maculopapular rash, pruritus, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Rare</b> (less than 0.1%): Hypersensitivity reactions, including angioedema, urticaria, rash, pruritus<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Uncommon</b> (0.1% to 1%): Arthropathies (arthralgia and arthritis)</p><p><b>Rare</b> (less than 0.1%): Atypical subtrochanteric and diaphyseal femoral fractures</p><p><b>Frequency not reported</b>: Osteonecrosis of the jaw (ONJ), leg cramps, increased or recurrent bone pain at pagetic sites and onset of pain at previously asymptomatic sites</p><p><b>Postmarketing reports</b>: Bone fracture, osteomalacia<sup>[Ref]</sup></p><p>At higher doses the incidence of increased or recurrent bone pain at pagetic sites and/or onset of pain at previously asymptomatic sites rise.  When therapy continues, pain resolves in some patients but persists in others.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Rare</b> (less than 0.1%): Confusion</p><p><b>Postmarketing reports</b>: Depression, hallucination<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Rare</b> (less than 0.1%): Paresthesia, peripheral neuropathy</p><p><b>Frequency not reported</b>: Headache</p><p><b>Postmarketing reports</b>: Neuropsychiatric events including amnesia<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Rare</b> (less than 0.1%): Exacerbation of asthma<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Rare</b> (less than 0.1%): Leukopenia, agranulocytosis pancytopenia<sup>[Ref]</sup></p><p id="ref_1">1. Saunders RL, Jr "Appearance of a gastric ulcer during diphosphonate therapy in a woman with CRST syndrome." South Med J 70 (1977): 1327-9</p><p id="ref_2">2. Beauchesne MF, Miller PF "Etidronate and alendronate in the treatment of postmenopausal osteoporosis." Ann Pharmacother 33 (1999): 587-99</p><p id="ref_3">3. Jaworski RC, Gibson M "Mitral and aortic valve abnormalities in a patient with fibrodysplasia ossificans progressiva." Pathology 15 (1983): 325-8</p><p id="ref_4">4. vanStaa TP, Leufkens H, Abenhaim L, Cooper C "Postmarketing surveillance of the safety of cyclic etidronate." Pharmacotherapy 18 (1998): 1121-8</p><p id="ref_5">5. "Product Information. Didronel Tablets (etidronate)." Procter and Gamble Pharmaceuticals, Cincinnati, OH. </p><p id="ref_6">6. Jones PB, McCloskey EV, Kanis JA "Transient taste-loss during treatment with etidronate ." Lancet 2 (1987): 637</p><p id="ref_7">7. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_8">8. "Product Information. Didronel I.V. Infusion (etidronate)." MGI Pharma Inc, Minnetonka, MN. </p><p id="ref_9">9. Lourwood DL "The pharmacology and therapeutic utility of bisphosphonates." Pharmacotherapy 18 (1998): 779-89</p><p id="ref_10">10. Evans RA, MacDonald D "Diphosphonates and painful feet." Aust N Z J Med 13 (1983): 175-6</p><p id="ref_11">11. Evans RA, Dunstan CR, Hills E, Wong SY "Pathologic fracture due to severe osteomalacia following low-dose diphosphonate treatment of Paget's disease of bone." Aust N Z J Med 13 (1983): 277-9</p><p id="ref_12">12. Gallacher SJ, Boyle IT, Capell HA "Pseudogout associated with the use of cyclical etidronate therapy." Scott Med J 36 (1991): 49</p><p id="ref_13">13. Mautalen C, Gonzalez D, Blumenfeld EL, Santini Araujo E, Schajowicz F "Spontaneous fractures of uninvolved bones in patients with Paget's disease during unduly prolonged treatment with disodium etidronate (EHDP)." Clin Orthop Jun (1986): 150-5</p><p id="ref_14">14. Boyce BF, Smith L, Fogelman I, Johnston E, Ralston S, Boyle IT "Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease." Lancet 1 (1984): 821-4</p><h2>More about Didronel (etidronate)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Drug class: bisphosphonates</li>
<li>FDA Alerts (3)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Didronel &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Heterotopic Ossification, Spinal Cord Injury</li>
<li>Heterotopic Ossification, Total Hip Arthroplasty</li>
<li>Hypercalcemia of Malignancy</li>
<li>Osteoporosis</li>
<li>Paget's Disease</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>